In Norway a diagnostic cut-off of anti-PT IgG level at 80 IU/ml is recommended (established with the Virion\Serion Bordetella Pertussis Toxin IgG assay). Within the first 2 years after the booster only 9 of 130 subjects had anti-PT IgG values above this level; however, 4 of these also had an anti-Prn IgG level above 50 IU/ml possibly indicating recent infection with B. pertussis. Antibodies against pertussis vaccine antigens were measured in a cross-sectional study in sera from children aged 6–12 years. Most of the children received a DTaP booster vaccine at age 7–8 years. At 6.4 geometric mean years after

primary vaccination, the pre-booster anti-PT IgG GM level was 7.3 IU/ml. In the first 100 days after the booster dose a rather moderate peak response was observed reaching up to an PS341 anti-PT IgG GM level of 45.6 IU/ml, which was followed Selleckchem Epacadostat by a subsequent decline the following years. Three years after the booster dose almost 20% of the sera contained an anti-PT

IgG level less than 5 IU/ml. These anti-PT IgG levels are lower than the corresponding levels reported in a Danish study where adults were given a booster vaccine with a single-component pertussis antigen (PT), in spite of the lower PT-antigen content in the Danish vaccine [10]. Also, in a Dutch study using an aP booster vaccine with a similar dose of PT and FHA [19], higher anti-PT IgG levels (187 EU/ml 28 days post booster) were found than we did in our study. The shorter interval between primary immunisation series and the booster dose in the Dutch study (4 years versus 6 years) and the shorter and exact blood sample timing after the booster (28 days versus 0–100 days (mean 59 days)) might possibly explain the more pronounced booster response. In line with our results they also noted a significant decline in the anti-PT IgG level 2 years after the booster.

Caution should nevertheless be taken when results from different laboratories are compared; however the methods used are similar and have been compared through inter-laboratory evaluations. The differences observed are more likely explained by different those vaccine history, different vaccines, different age groups, and possible interference from other vaccine antigens. In line with the decrease of pertussis-specific antibodies, a higher number of sera with an anti-PT IgG level ≤5 IU/ml were found with increasing time since booster. Although there is no established serological correlate of protection against pertussis, it is likely that subjects with low vaccine-induced anti-PT IgG levels are less protected than subjects with higher levels [20] and [21].